Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER
European Journal of Heart Failure
DECEMBER 13, 2023
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. The primary outcome was a composite of cardiovascular death or worsening heart failure. In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.
Let's personalize your content